Next Article in Journal
Predicting the Influence of Shear on the Seismic Response of Bridge Columns
Next Article in Special Issue
Probing New Antileukemia Agents That Target FLT3 and BCL-2 from Traditional Concoctions through a Combination of Mass Spectrometry Analysis and Consensus Docking Methods
Previous Article in Journal
Supporting Argumentation Dialogues in Group Decision Support Systems: An Approach Based on Dynamic Clustering
Previous Article in Special Issue
Anthraquinone Rhein Exhibits Antibacterial Activity against Staphylococcus aureus
 
 
Review
Peer-Review Record

A Look at the Importance of Chirality in Drug Activity: Some Significative Examples

Appl. Sci. 2022, 12(21), 10909; https://doi.org/10.3390/app122110909
by Jessica Ceramella 1, Domenico Iacopetta 1, Angelica Franchini 2, Michele De Luca 1, Carmela Saturnino 3, Inmaculada Andreu 4,5, Maria Stefania Sinicropi 1,* and Alessia Catalano 2
Reviewer 2: Anonymous
Reviewer 3: Anonymous
Appl. Sci. 2022, 12(21), 10909; https://doi.org/10.3390/app122110909
Submission received: 5 October 2022 / Revised: 19 October 2022 / Accepted: 25 October 2022 / Published: 27 October 2022

Round 1

Reviewer 1 Report

 

Comments for author File: Comments.pdf

Author Response

The responses are in the attached file

Author Response File: Author Response.pdf

Reviewer 2 Report

send separately

Comments for author File: Comments.docx

Author Response

The responses are in the attached file

Author Response File: Author Response.pdf

Reviewer 3 Report

In the paper” a Flash on the importance OF Chirality in Drug Activity: Some Significative examples” by Ceramella et al.  the Authors offer an overview of the activity of chiral drugs, with an emphasis on the effect of stereochemistry on drug action.

 

However, for some pf the reported drugs there is no indication of stereochemical effect, mostly because the enantiomer of the drug under use is not available. My advice is to remove those examples from the review , as they add no further knowledge on the subject (e,g,  angiotensin-converting enzyme inhibitors, orciprenaline,  astragalin, some of the anticancer drugs listed in chapter 9, and JAK inhibitors).

Author Response

The responses are in the attached file

Author Response File: Author Response.pdf

Round 2

Reviewer 2 Report

The extensive revised version has been conducted in a short time. The paper and the table has been improved and can thus be published as is. 

Back to TopTop